NO20000855D0 - Radioaktive liposomer til terapi - Google Patents

Radioaktive liposomer til terapi

Info

Publication number
NO20000855D0
NO20000855D0 NO20000855A NO20000855A NO20000855D0 NO 20000855 D0 NO20000855 D0 NO 20000855D0 NO 20000855 A NO20000855 A NO 20000855A NO 20000855 A NO20000855 A NO 20000855A NO 20000855 D0 NO20000855 D0 NO 20000855D0
Authority
NO
Norway
Prior art keywords
liposomes
therapy
radioactive
radioactive liposomes
ionophores
Prior art date
Application number
NO20000855A
Other languages
English (en)
Other versions
NO312708B1 (no
NO20000855L (no
Inventor
Roy H Larsen
Gjermund Henriksen
Original Assignee
Anticancer Therapeutic Inventi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anticancer Therapeutic Inventi filed Critical Anticancer Therapeutic Inventi
Priority to NO20000855A priority Critical patent/NO312708B1/no
Publication of NO20000855D0 publication Critical patent/NO20000855D0/no
Priority to PL358541A priority patent/PL201398B1/pl
Priority to UA2002086850A priority patent/UA73160C2/uk
Priority to EA200200793A priority patent/EA005624B1/ru
Priority to JP2001559512A priority patent/JP4933712B2/ja
Priority to EP01910251A priority patent/EP1257299B9/en
Priority to AT01910251T priority patent/ATE300316T1/de
Priority to DE60112251T priority patent/DE60112251T2/de
Priority to ES01910251T priority patent/ES2247069T3/es
Priority to BR0108572-7A priority patent/BR0108572A/pt
Priority to DK01910251T priority patent/DK1257299T3/da
Priority to KR1020027010848A priority patent/KR100822566B1/ko
Priority to PCT/NO2001/000065 priority patent/WO2001060417A2/en
Priority to US09/790,260 priority patent/US6592843B2/en
Priority to MXPA02008110A priority patent/MXPA02008110A/es
Priority to CZ20023164A priority patent/CZ299032B6/cs
Priority to AU3782701A priority patent/AU3782701A/xx
Priority to AU2001237827A priority patent/AU2001237827B2/en
Priority to CA002400994A priority patent/CA2400994C/en
Priority to CNB018053726A priority patent/CN100350981C/zh
Priority to NZ520848A priority patent/NZ520848A/en
Publication of NO20000855L publication Critical patent/NO20000855L/no
Publication of NO312708B1 publication Critical patent/NO312708B1/no
Priority to ZA200206500A priority patent/ZA200206500B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20000855A 2000-02-21 2000-02-21 Radioaktive liposomer til terapi NO312708B1 (no)

Priority Applications (22)

Application Number Priority Date Filing Date Title
NO20000855A NO312708B1 (no) 2000-02-21 2000-02-21 Radioaktive liposomer til terapi
NZ520848A NZ520848A (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
DK01910251T DK1257299T3 (da) 2000-02-21 2001-02-21 Radioaktive, terapeutiske liposomer
PCT/NO2001/000065 WO2001060417A2 (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
EA200200793A EA005624B1 (ru) 2000-02-21 2001-02-21 Радиоактивные терапевтические липосомы
JP2001559512A JP4933712B2 (ja) 2000-02-21 2001-02-21 放射線治療用リポソーム
EP01910251A EP1257299B9 (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
AT01910251T ATE300316T1 (de) 2000-02-21 2001-02-21 Radioaktive therapeutische liposomen
DE60112251T DE60112251T2 (de) 2000-02-21 2001-02-21 Radioaktive therapeutische liposomen
ES01910251T ES2247069T3 (es) 2000-02-21 2001-02-21 Liposomas terapeuticos radioactivos.
BR0108572-7A BR0108572A (pt) 2000-02-21 2001-02-21 Sistema conjugador, método para preparar um sistema conjugador radiorrotulado, uso do sistema conjugador, método para utilizar o sistema conjugador, e, kit para a preparação do sistema conjugador
PL358541A PL201398B1 (pl) 2000-02-21 2001-02-21 System koniugatora radionuklid-liposom, sposób jego wytwarzania, zastosowanie systemu koniugatora do wytwarzania roztworu farmaceutycznego, zastosowanie terapeutyczne systemu koniugatora oraz zestaw do wytwarzania systemu koniugatora
KR1020027010848A KR100822566B1 (ko) 2000-02-21 2001-02-21 방사성 치료 리포좀
UA2002086850A UA73160C2 (uk) 2000-02-21 2001-02-21 Кон'югаційна система, що являє собою радіоактивні терапевтичні ліпосоми, спосіб їх одержання та застосування
US09/790,260 US6592843B2 (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
MXPA02008110A MXPA02008110A (es) 2000-02-21 2001-02-21 Liposomas terapeuticos radioactivos.
CZ20023164A CZ299032B6 (cs) 2000-02-21 2001-02-21 Konjugátorový systém
AU3782701A AU3782701A (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
AU2001237827A AU2001237827B2 (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
CA002400994A CA2400994C (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
CNB018053726A CN100350981C (zh) 2000-02-21 2001-02-21 有放射活性的治疗性脂质体
ZA200206500A ZA200206500B (en) 2000-02-21 2002-08-14 Radioactive therapeutic liposomes.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20000855A NO312708B1 (no) 2000-02-21 2000-02-21 Radioaktive liposomer til terapi

Publications (3)

Publication Number Publication Date
NO20000855D0 true NO20000855D0 (no) 2000-02-21
NO20000855L NO20000855L (no) 2001-08-22
NO312708B1 NO312708B1 (no) 2002-06-24

Family

ID=19910768

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000855A NO312708B1 (no) 2000-02-21 2000-02-21 Radioaktive liposomer til terapi

Country Status (21)

Country Link
US (1) US6592843B2 (no)
EP (1) EP1257299B9 (no)
JP (1) JP4933712B2 (no)
KR (1) KR100822566B1 (no)
CN (1) CN100350981C (no)
AT (1) ATE300316T1 (no)
AU (2) AU3782701A (no)
BR (1) BR0108572A (no)
CA (1) CA2400994C (no)
CZ (1) CZ299032B6 (no)
DE (1) DE60112251T2 (no)
DK (1) DK1257299T3 (no)
EA (1) EA005624B1 (no)
ES (1) ES2247069T3 (no)
MX (1) MXPA02008110A (no)
NO (1) NO312708B1 (no)
NZ (1) NZ520848A (no)
PL (1) PL201398B1 (no)
UA (1) UA73160C2 (no)
WO (1) WO2001060417A2 (no)
ZA (1) ZA200206500B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
US8029795B2 (en) * 1999-12-30 2011-10-04 Gwathmey, Inc. Targeted iron chelator delivery system
JP2003535913A (ja) * 2000-06-16 2003-12-02 スローン−ケッタリング インスティトゥート フォー カンサー リサーチ キレートアクチニウム−２２５のリポソーム封入およびその使用
US20040166060A1 (en) * 2000-06-16 2004-08-26 Sloan Kettering Institute For Cancer Research Liposomal encapsulation of alpha particle emittors and uses thereof
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US6869591B2 (en) * 2002-03-26 2005-03-22 Barnes-Jewish Hospital Paramagnetic particles that provide improved relaxivity
GB0213261D0 (en) * 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
NZ606996A (en) * 2003-04-15 2014-08-29 Algeta As Thorium-227 for use in radiotherapy of soft tissue disease
WO2005053605A2 (en) * 2003-09-09 2005-06-16 Gilead Sciences, Inc. Therapeutic liposomes
US8142758B2 (en) 2004-02-20 2012-03-27 Algeta As Alpha-emitting hydroxyapatite particles
US20070053845A1 (en) * 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
WO2005084710A2 (en) * 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
US20070065359A1 (en) * 2005-03-14 2007-03-22 Shiladitya Sengupta Nanocells for diagnosis and treatment of diseases and disorders
US8709380B1 (en) * 2006-02-07 2014-04-29 Sirius Medicine, Llc Targeting agents for enhancing radiation therapy
US20070224115A1 (en) * 2006-03-22 2007-09-27 The Regents Of The University Of California Polymeric chelators for radionuclide delivery systems
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
US20100178244A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
IN2012DN01449A (no) 2009-07-17 2015-06-05 Univ Denmark Tech Dtu
JP2011111438A (ja) * 2009-11-30 2011-06-09 Akita Univ 有機金属錯体を有効成分として含有する抗がん剤
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
BR112013014735A2 (pt) 2010-12-14 2016-10-04 Rigshospitalet captura de radionuclídeos em composições de nanopartículas
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
DE102011079031A1 (de) * 2011-07-12 2013-01-17 Algeta Asa Flüssigkeitsbehälter
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes
ES2820734T3 (es) 2013-03-11 2021-04-22 Univ Wayne State Liposomas que comprenden criptandos de europio y su uso
MX369632B (es) * 2015-02-26 2019-11-14 Sciencons AS Soluciones radiofarmaceuticas con propiedades ventajosas.
US9433690B1 (en) 2015-02-26 2016-09-06 Sciencons AS Radiopharmaceutical solutions with advantageous properties
ES2657388T3 (es) * 2015-02-26 2018-03-05 Sciencons AS Disoluciones radiofarmacéuticas con propiedades ventajosas
PL3111959T3 (pl) * 2015-07-03 2018-03-30 Oncoinvent As Radioterapeutyczne cząstki i zawiesiny
UA125749C2 (uk) 2016-03-24 2022-06-01 Байєр Фарма Акцієнгезелльшафт Радіофармацевтичні комплекси
CN109689115A (zh) 2016-06-10 2019-04-26 拜耳制药股份公司 放射性药物配合物
EP3474904A1 (en) * 2016-06-24 2019-05-01 Sciencons AS Preparation of 212pb labeled monoclonal antibodies
WO2018207105A1 (en) 2017-05-11 2018-11-15 Alpha Tau Medical Ltd. Polymer coatings for brachytherapy devices
AU2019247818B2 (en) 2018-04-02 2021-10-14 Alpha Tau Medical Ltd. Controlled release of radionuclides
CA3148382A1 (en) 2019-07-25 2021-01-28 Bayer As Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer
JP2024503995A (ja) 2020-12-16 2024-01-30 アルファ タウ メディカル リミテッド ベータ線治療を強化した拡散アルファ放射体放射線治療

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310506A (en) * 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
IE58659B1 (en) * 1984-10-22 1993-11-03 Vestar Inc Use of a micellular particle composition encapsulating a chemotherapeutic agent for intravenous targeting to tumors
ATE88642T1 (de) * 1987-11-04 1993-05-15 Vestar Inc Zusammensetzung und verfahren zur anwendung von in liposomen eingeschlossenen verbindungen in der neutroneneinfangtherapie von tumoren.
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
ATE210464T1 (de) * 1992-06-09 2001-12-15 Neorx Corp BIOTIN-DOTA KONJUGATE UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
GB9420390D0 (en) * 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
JP5064608B2 (ja) * 1998-05-26 2012-10-31 スローン−ケッタリング インスティトゥート フォー カンサー リサーチ アルファ粒子放出構成物およびその使用方法

Also Published As

Publication number Publication date
PL201398B1 (pl) 2009-04-30
CZ299032B6 (cs) 2008-04-09
ES2247069T3 (es) 2006-03-01
ATE300316T1 (de) 2005-08-15
CA2400994A1 (en) 2001-08-23
DE60112251D1 (de) 2005-09-01
WO2001060417A3 (en) 2002-02-07
JP4933712B2 (ja) 2012-05-16
EA005624B1 (ru) 2005-04-28
DE60112251T2 (de) 2006-03-30
NZ520848A (en) 2005-02-25
AU2001237827B2 (en) 2007-11-22
CN1404402A (zh) 2003-03-19
NO312708B1 (no) 2002-06-24
CN100350981C (zh) 2007-11-28
PL358541A1 (en) 2004-08-09
EP1257299A2 (en) 2002-11-20
JP2003522808A (ja) 2003-07-29
AU2001237827B8 (en) 2001-08-27
CZ20023164A3 (cs) 2003-04-16
US6592843B2 (en) 2003-07-15
NO20000855L (no) 2001-08-22
EA200200793A1 (ru) 2003-02-27
CA2400994C (en) 2009-07-07
KR20020092963A (ko) 2002-12-12
WO2001060417A2 (en) 2001-08-23
AU3782701A (en) 2001-08-27
KR100822566B1 (ko) 2008-04-16
ZA200206500B (en) 2003-08-14
MXPA02008110A (es) 2003-12-11
BR0108572A (pt) 2002-11-19
DK1257299T3 (da) 2005-11-21
EP1257299B9 (en) 2005-11-30
US20010048914A1 (en) 2001-12-06
EP1257299B1 (en) 2005-07-27
UA73160C2 (uk) 2005-06-15

Similar Documents

Publication Publication Date Title
NO20000855D0 (no) Radioaktive liposomer til terapi
HUP0105489A2 (hu) Kit fehérjék ittrium-90-nel való jelölésére
GB0105772D0 (en) Use
CY1111396T1 (el) Ρινικη χορηγηση μετοκλοπραμιδης για την αγωγη της γαστροπαρεσης
MXPA04009163A (es) Nuevos compuestos.
GT199900019A (es) Formulas farmaceuticamente estables de solucion de oxaliplatino.
EP0249735A3 (en) Pharmaceutical preparations comprising as active agent 2-phenyl-1.2-benzisoselenazol-3(2h)-one, for the treatment of diseases caused by oxidative stress
ES2160410T3 (es) Preparados de complejos de protrombina inmunotolerantes.
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
TR200200263T2 (tr) Yeni seçiçi retinoid agonistleri
SE0003537L (sv) Hudvänligt lim
HK1029932A1 (en) Use of mirtazapine for the manufacture of a medicament for treating sleep apneas.
AP2001002274A0 (en) Rescorcinol derivatives.
ATE404212T1 (de) Verwendung von selenithältigen verbindungen zur topischen oder bukkalen anwendung
IL150367A0 (en) Method for the preparation of citalopram
MY137580A (en) Radioactive therapeutic liposomes
DK0996613T3 (da) Fremstilling af rent cis-tramadol-hydrochlorid
UY26085A1 (es) N-[-(4-aminofenil)-2,3-dihidro-1,4-benzodioxina-2-metanamina su preparacion y su aplicacion en terapeutica
ATE328899T1 (de) Zellkernlokalisierendes protein für beta-catenin
DE60124148D1 (de) Kalzilytische verbindungen
TR200100906T2 (tr) Trombin inhibitörleri olarak benzamid türevleri
Lebedev et al. Simulation of Photographic Measurement Process of the Stellar Magnetic Fields
ES545563A0 (es) Procedimiento para producir clorhidrato de l-norcarnitina
UA30267A (uk) Протирикетсійний фітозасіб
ECSP003635A (es) Formas de admnistracion de tramadol retardadas, mediante un revestimiento que contiene la sustancia activa tramadol en forma de sacarinato de tramadol asi como eventualmente otros excipientes

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees